STOCK TITAN

Ironwood Pharmaceuticals (IRWD) 10-K Filings

IRWD NASDAQ

Here are the 10-K annual reports from Ironwood Pharmaceuticals, Inc. (IRWD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow IRWD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRWD filings page.

Rhea-AI Summary

Ironwood Pharmaceuticals focuses on gastrointestinal and rare diseases, built around LINZESS and its apraglutide pipeline. The company co-commercializes LINZESS for IBS-C and chronic constipation with AbbVie in the U.S. and relies on partners such as AbbVie, Astellas and AstraZeneca globally.

Through its VectivBio acquisition, Ironwood is advancing apraglutide for short bowel syndrome; after positive Phase III data, the FDA required a confirmatory Phase III trial (STARS-2), with site initiations expected in the second quarter of 2026. Ironwood ceased development of IW-3300 after Phase II results.

Revenue concentration is high, with the U.S. contributing 97.7% of 2025 revenue and LINZESS collaborations comprising substantially all revenue. Government pricing pressure is rising: LINZESS was selected for Medicare price negotiation, and its Maximum Fair Price from 2027 will be $136 for a 30-day supply, alongside a LINZESS list price cut effective January 1, 2026.